24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.

Additional Information

Item Type	Article
Keywords	Antiviral Agents/administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis C, Chronic/diagnosis/drug therapy, Human, Interferon-alpha/administration & dosage, Male, Prospective Studies, Ribavirin/administration & dosage, Risk Assessment, Sensitivity and Specificity, Time Factors, Treatment Outcome, *Viral Load, Antiviral Agents, administration & dosage, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis C, Chronic, diagnosis, drug therapy, Human, Interferon-alpha, administration & dosage, Male, Prospective Studies, Ribavirin, administration & dosage, Risk Assessment, Sensitivity and Specificity, Time Factors, Treatment Outcome, Viral Load
Faculty and Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID	11866304
ISI	173880400050

Report this Record Edit item (admin only) View this record in elements